ASLAN Pharmaceuticals
A clinical-stage immunology and oncology centered company focused biopharmaceuticals developing innovative treatments to transform the lives of patients.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 366.7x EV/Revenue -26.5x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $12.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1525 %) | - | - | - | (358 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1569 %) | - | - | - | (368 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 553 % | - | - | - | 354 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company that was focused on the development of novel therapeutics for immunology and oncology. The company's lead product candidate was eblasakimab, a monoclonal antibody that targets the IL-13 receptor, which was being developed for the treatment of atopic dermatitis.
In July 2024, the company announced that it had filed for voluntary liquidation of its sole operating subsidiary and was commencing steps to place itself into voluntary liquidation. This decision followed a strategic review of the company's operations and financial situation. Prior to this, the company was actively engaged in clinical trials and sought to commercialize its product candidates in global markets. The company's business model was centered on research and development, with the goal of bringing new treatments to market and generating revenue through drug sales and licensing agreements.
Keywords: biopharmaceutical, immunology, oncology, clinical-stage, antibody, atopic dermatitis, liquidation, therapeutics, IL-13 receptor, drug development